FDA Approves OGSIVEO — SpringWorks Therapeutics, Inc.

# FDA Approves SpringWorks Therapeutics' OGSIVEO for Dercum Disease Treatment SpringWorks Therapeutics, Inc. received FDA approval for OGSIVEO (nirogacestat), an oral gamma-secretase inhibitor for the treatment of Dercum disease, marking the first FDA-approved therapy for this rare genetic disorder and potentially opening a significant new revenue stream for the company. The approval positions SpringWorks to capture market share in the orphan drug space, where OGSIVEO will face limited competition and benefit from regulatory incentives including extended market exclusivity.